PolyPeptide Group (PPGN) Stock Overview

PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the Americas, the Asia Pacific, and internationally. It focuses on peptide- and oligonucleotide-based therapies for pharma and biotech customers. The company also develops and manufactures active ingredients for therapies that range from the treatment of metabolic diseases, such as diabetes or obesity, as well as cancer and cardiovascular, or neurological disorders. In addition, it engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. Further, the company is involved in manufacturing peptides for commercially approved peptide therapeutics. Additionally, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. The company offers regulatory affair support services. It has a collaboration agreement with Numaferm for peptide development and production The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.